17 result(s)
IN VIVO
Ex VIVO
Safety/Tolerability of a One-Time Infusion of Lonvoguran Ziclumeran (lonvo-z; NTLA-2002) for Hereditary Angioedema
2025 American College of Allergy, Asthma & Immunology Annual Scientific Meeting
Barriers to Achieving Normalization Among People Living with HAE On Existing Treatments
2025 American College of Allergy, Asthma & Immunology Annual Scientific Meeting
Nexiguran Ziclumeran Gene Editing in Hereditary ATTR with Polyneuropathy
The New England Journal of Medicine
CRISPR Gene Editing With Nexiguran Ziclumeran in Hereditary ATTR With Polyneuropathy: Phase 1 24-Month Report
5th International ATTR Amyloidosis Meeting for Patients and Doctors
Long-Term Durability of CRISPR-Based Gene Editing of KLKB1 from Phase 1 of a Phase 1/2 trial of Patients with Hereditary Angioedema
2025 European Academy of Allergy and Clinical Immunology Annual Meeting
CRISPR Gene Editing With Nexiguran Ziclumeran in Hereditary ATTR With Polyneuropathy: Phase 1 Interim Report
2025 Peripheral Nerve Society Annual Meeting
CRISPR Gene Editing With Nexiguran Ziclumeran in ATTR Cardiomyopathy: Treatment Effect in Hereditary vs. Wild-Type Disease
Heart Failure Congress 2025
CRISPR-Based NTLA-2002 Improves Quality of Life in Patients With Hereditary Angioedema
American Academy of Allergy, Asthma & Immunology and World Allergy Organization Joint Congress
Nexiguran Ziclumeran (nex-z, Also Known as NTLA-2001), an Investigational In Vivo CRISPR-Based Therapy for Patients With Transthyretin Amyloidosis With Cardiomyopathy (ATTR-CM): Interim Report of the Phase 1 Study
American Heart Association Scientific Sessions
CRISPR-Cas9 Gene Editing with Nexiguran Ziclumeran for ATTR Cardiomyopathy
The New England Journal of Medicine
Results from Phase 2 Study of NTLA-2002 for Hereditary Angioedema
Intellia Therapeutics Sponsored Event
Results From a Phase 2, Randomized, Placebo-Controlled Trial of CRISPR-Based Therapy NTLA-2002 for Hereditary Angioedema
American College of Allergy, Asthma & Immunology 2024 Annual Scientific Meeting
CRISPR-Based Therapy for Hereditary Angioedema
The New England Journal of Medicine
Activity of Follow-On Dosing for an Investigational In Vivo CRISPR-Based Lipid Nanoparticle Therapy in Transthyretin Amyloidosis
Peripheral Nerve Society Annual Meeting
NTLA-2002 Long-Term Phase 1 Data Update from the Ongoing Phase 1/2 Study
Intellia Therapeutics Sponsored Event
CRISPR-Based Gene Editing of KLKB1 Resulted in Long-Term Plasma Kallikrein Protein Reduction and Decreased Attack Rate in Patients With Hereditary Angioedema
European Academy of Allergy and Clinical Immunology Congress 2024
CRISPR-Cas9 In Vivo Gene Editing of KLKB1 for Hereditary Angioedema
New England Journal of Medicine
